Publication:
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

Simple item page
dc.contributor.authorGarcia-Gutierrez, Valentin
dc.contributor.authorLuna, Alejandro
dc.contributor.authorAlonso-Dominguez, Juan M
dc.contributor.authorEstrada, Natalia
dc.contributor.authorBoque, Concepcion
dc.contributor.authorXicoy, Blanca
dc.contributor.authorGiraldo, Pilar
dc.contributor.authorAngona, Anna
dc.contributor.authorAlvarez-Larran, Alberto
dc.contributor.authorSanchez-Guijo, Fermin
dc.contributor.authorRamirez, Maria Jose
dc.contributor.authorMora, Elvira
dc.contributor.authorVelez, Patricia
dc.contributor.authorRosell, Ana
dc.contributor.authorColorado-Araujo, Mercedes
dc.contributor.authorCuevas, Beatriz
dc.contributor.authorSagües, Miguel
dc.contributor.authorCortes, Montserrat
dc.contributor.authorPerez-Encinas, Manuel
dc.contributor.authorCasado Montero, Luis Felipe
dc.contributor.authorMoreno-Vega, Melania
dc.contributor.authorSerrano, Luis
dc.contributor.authorGomez, Valle
dc.contributor.authorGarcia-Hernandez, Carmen
dc.contributor.authorLakhwani, Sunil
dc.contributor.authorPaz-Coll, Antonio
dc.contributor.authorde-Paz, Raquel
dc.contributor.authorSuarez-Varela, Sara
dc.contributor.authorFernandez-Ruiz, Andres
dc.contributor.authorPerez-Lopez, Raul
dc.contributor.authorOrtiz-Fernandez, Almudena
dc.contributor.authorJimenez-Velasco, Antonio
dc.contributor.authorSteegmann-Olmedillas, Juan Luis
dc.contributor.authorHernandez-Boluda, Juan Carlos
dc.date.accessioned2023-02-09T10:41:35Z
dc.date.available2023-02-09T10:41:35Z
dc.date.issued2021-02-09
dc.description.abstractDespite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses.
dc.identifier.citationGarcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021 Feb 9;11(2):16
dc.identifier.doi10.1038/s41408-021-00420-8
dc.identifier.essn2044-5385
dc.identifier.pmcPMC7873237
dc.identifier.pmid33563899
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873237/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41408-021-00420-8.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17137
dc.issue.number2
dc.journal.titleBlood cancer journal
dc.journal.titleabbreviationBlood Cancer J
dc.language.isoen
dc.organizationHospital Universitario de Puerto Real
dc.organizationÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.organizationAGS - Jerez, Costa Noroeste y Sierra de Cáidz
dc.page.number4
dc.provenanceRealizada la curación de contenido 20/02/2025
dc.publisherNature Publishing Group
dc.pubmedtypeLetter
dc.relation.publisherversionhttps://doi.org/10.1038/s41408-021-00420-8
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.subjectProtein Kinase Inhibitors
dc.subjectPyrazoles
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.subject.decsVolición
dc.subject.decsFosfotransferasas
dc.subject.decsTirosina
dc.subject.decsLeucemia mieloide
dc.subject.decsPreparaciones farmacéuticas
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshFemale
dc.subject.meshFusion Proteins, bcr-abl
dc.subject.meshHumans
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNiacinamide
dc.titleSafety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC7873237.pdf
Size:
335.96 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario de Jerez de la Frontera
SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía